Health Care [ 5/12 ] | Biotechnology [ 39/75 ]
NASDAQ | Common Stock
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota.
Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 24 | -3.01 Increased by +7.09% | - |
| May 10, 24 | -2.41 Decreased by -535.21% | - |
| Mar 25, 24 | -1.89 Decreased by -238.18% | - |
| Nov 8, 23 | -1.51 Decreased by -77.09% | - |
| Aug 10, 23 | -3.24 Decreased by -575.00% | -4.50 Increased by +28.00% |
| May 10, 23 | -0.38 Increased by +26.92% | -0.09 Decreased by -322.22% |
| Mar 23, 23 | -0.56 Decreased by -40.00% | -0.34 Decreased by -64.71% |
| Nov 10, 22 | -0.85 Decreased by -304.76% | -0.40 Decreased by -112.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 0.00 Decreased by N/A% | -4.83 M Increased by +30.45% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 2.85 M Increased by +2.56 K% | -3.88 M Increased by +93.94% | Decreased by -136.24% Increased by +99.77% |
| Dec 31, 23 | 2.85 M Increased by +35.46 K% | -3.04 M Increased by +88.45% | Decreased by -106.89% Increased by +99.97% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -2.42 M Increased by +93.98% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -6.95 M Increased by +69.48% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 107.00 K Decreased by -69.77% | -63.94 M Decreased by -160.40% | Decreased by -59.76 K% Decreased by -761.52% |
| Dec 31, 22 | 8.00 K Decreased by -99.01% | -26.32 M Decreased by -38.14% | Decreased by -329.02 K% Decreased by -13.82 K% |
| Sep 30, 22 | 138.00 K Decreased by -98.78% | -40.11 M Decreased by -302.91% | Decreased by -29.07 K% Decreased by -33.02 K% |